Skip to main content

FDA Panel Gives the Green Light for More Anti-NGF Testing


March 13, 2012 — The US Food and Drug Administration (FDA) Arthritis Advisory Committee has unanimously agreed to let Janssen, Pfizer, and Regeneron resume clinical trials with their respective anti–nerve growth factor (NGF) drugs, despite cases of joint destruction and osteonecrosis associated with their use.
The panel voted 21 yes, 0 no, with no abstentions, when asked whether the risk–benefit profile of the anti-NGF agents indicated a role for their ongoing development.
The drugs are being developed for the treatment of a variety of chronic painful conditions, including osteoarthritis, chronic lower back pain, diabetic peripheral neuropathy, postherpetic neuralgia, chronic pancreatitis, endometriosis, interstitial cystitis, vertebral fracture, thermal injury, and cancer pain.
Nerve growth factor promotes pain by inducing hyperalgesia in various disease states through various molecular mechanisms, resulting in sensitization of peripheral nociceptors, axonal sprouting, and sensory and sympathetic fiber innervation into damaged tissues, according to background material provided in a memo by Bob A. Rappaport, MD, director of the FDA's Division of Anesthesia, Analgesia, and Addiction Products in Rockville, Maryland.
The anti-NGF drugs attenuate this process and are considered a significant and novel strategy for the treatment of chronic pain.
In April 2010, the FDA put Pfizer's clinical trial of its anti-NGF agent tanezumab on hold after reports of unusual and unexpected cases of osteonecrosis and avascular necrosis that led to joint replacement in patients with osteoarthritis.
In December 2010, Janssen reported a case of avascular necrosis of the hip in a patient with no known history of osteoarthritis, who was given the manufacturer's anti-NGF agent fulranumab for chronic low back pain. Soon after, Regeneron's trial of its anti-NGF agent, REGN475, was halted and by January 2011, all 3 trials were put on clinical hold. Only studies in patients with terminal cancer who had intractable severe pain resulting from bone metastases were allowed to continue.
Starting Over
"This is very complex. One of the problems we are grappling with here is the quality of the data, and the reason is because the preclinical studies did not indicate that we needed to have concerns about rapidly progressive osteoarthritis, the health of subchondral bone, or concerns about joints other than the index joint," said David Blumenthal, MD, from Case Western Reserve University in Cleveland, Ohio.
"So now we're doing a post hoc, retrospective analysis trying to reconstruct what happened in these patients who appeared to have had bad outcomes," he said.
Dr. Blumenthal suggested that the sponsors go back to the drawing board and design new studies.
"We're at the start of something that's going to go on through many iterations for many years. There will be other investigational new drugs, and safety measures will have to be in place for them," he pointed out. "When you look at it from that perspective, should the people who developed this very first agent be excluded from having their drug under consideration? The possibility here, if the sponsors and the FDA are agreeable, is to start over, knowing what we know now, and taking another look in a way that maximizes patient safety."
Use for Other Painful Conditions
Robert G. Lahita, MD, PhD, from the University of Medicine and Dentistry of New Jersey in Newark, reminded the panel that there were other painful conditions besides osteoarthritis. "One of our issues is the management of cancer, in stage 4, very severe cancer pain. I don't think this should be thrown out," he said.
John Kelly, MD, from the University of Pennsylvania Health System, Philadelphia, agreed that the anti-NGF drugs could have their niche. "We can't throw the baby out with the bathwater, and I don't think we should dismiss this. It is a useful agent for some patients," he said.
Penney Cowan, the founder and executive director of the American Chronic Pain Association, from Rocklin, California, and the consumer representative on the panel, said it was important for patients with chronic pain to have some hope. She agreed that informed consent was very important for future trials, but added, "I wouldn't want to throw these agents away."
The panel also had suggestions for screening, safety monitoring, and follow-up assessments in the continuing studies.
Eric A. Walker, MD, from Milton S. Hershey Medical Center in Hershey, Pennsylvania, said obtaining baseline radiographs and magnetic resonance imaging of the pelvis are crucial.
Statistician James Neaton, PhD, from the University of Minnesota in Minneapolis, called for follow-up to be extended in every study participant out to 6 months, and even longer, and that the companies consider some sort of collaboration to combine their safety data.
Arthritis Advisory Committee Meeting. Silver Spring, Maryland. March 12, 2012.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Sitting at Work Raises All-Cause and CV Mortality Risk

May 21, 2012 (Lyon, France) — Sitting at work raises the risk of dying from cardiovascular (CV) and metabolic diseases, as well as the risk of dying from all causes, regardless of any exercise in which the individual may engage. That was the finding of a study reported here at the 19th European Congress on Obesity (ECO) by Anne Grunseit, PhD, from the Prevention Research Collaboration in the School of Public Health at the University of Sydney, Australia, and Norwegian colleagues. Research is increasingly focusing on sedentary behavior with low energy expenditure, including sitting and lying down, as behavioral risk factors for obesity and chronic disease. Sitting occurs during travel, while watching television, using computers, and reading. But with people often spending at least 9 hours a day at work, with fewer than 20% of jobs requiring physical exertion, and with many people spending at least 4 hours a day sitting at work, the sedentary time at work is high, and many people ar...